192 related articles for article (PubMed ID: 34786207)
1. A transcriptional signature detects homologous recombination deficiency in pancreatic cancer at the individual level.
Zhuang S; Chen T; Li Y; Wang Y; Ai L; Geng Y; Zou M; Liu K; Xu H; Wang L; Zhao Z; Chang Z; Gu Y
Mol Ther Nucleic Acids; 2021 Dec; 26():1014-1026. PubMed ID: 34786207
[TBL] [Abstract][Full Text] [Related]
2. Discovering a qualitative transcriptional signature of homologous recombination defectiveness for prostate cancer.
Li Y; Zhao Z; Ai L; Wang Y; Liu K; Chen B; Chen T; Zhuang S; Xu H; Zou M; Gu Y; Li X
iScience; 2021 Oct; 24(10):103135. PubMed ID: 34622176
[TBL] [Abstract][Full Text] [Related]
3. Molecular signatures of BRCAness analysis identifies PARP inhibitor Niraparib as a novel targeted therapeutic strategy for soft tissue Sarcomas.
Li H; Tu J; Zhao Z; Chen L; Qu Y; Li H; Yao H; Wang X; Lee DF; Shen J; Wen L; Huang G; Xie X
Theranostics; 2020; 10(21):9477-9494. PubMed ID: 32863940
[No Abstract] [Full Text] [Related]
4. Homologous recombination deficiency is inversely correlated with microsatellite instability and identifies immunologically cold tumors in most cancer types.
Budczies J; Kluck K; Beck S; Ourailidis I; Allgäuer M; Menzel M; Kazdal D; Perkhofer L; Kleger A; Schirmacher P; Seufferlein T; Stenzinger A
J Pathol Clin Res; 2022 Jul; 8(4):371-382. PubMed ID: 35384413
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of Homologous Recombination Deficiency in First-Line PARP Inhibitor Maintenance Clinical Trials and Further Implication of Personalized Treatment in Ovarian Cancer.
Paik ES; Chang HK; Lee S
Cancers (Basel); 2023 Jun; 15(12):. PubMed ID: 37370704
[TBL] [Abstract][Full Text] [Related]
6. Comparative Assessment of Diagnostic Homologous Recombination Deficiency-Associated Mutational Signatures in Ovarian Cancer.
Sztupinszki Z; Diossy M; Borcsok J; Prosz A; Cornelius N; Kjeldsen MK; Mirza MR; Szallasi Z
Clin Cancer Res; 2021 Oct; 27(20):5681-5687. PubMed ID: 34380641
[TBL] [Abstract][Full Text] [Related]
7. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
Liu FW; Tewari KS
Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795
[TBL] [Abstract][Full Text] [Related]
8. A high homologous recombination deficiency score is associated with poor survival and a non-inflamed tumor microenvironment in head and neck squamous cell carcinoma patients.
Chen Y; Zheng X; Lin J; Gao X; Xiong J; Liu J; Fei Z; Chen C
Oral Oncol; 2022 May; 128():105860. PubMed ID: 35428026
[TBL] [Abstract][Full Text] [Related]
9. Combined homologous recombination repair deficiency and immune activation analysis for predicting intensified responses of anthracycline, cyclophosphamide and taxane chemotherapy in triple-negative breast cancer.
Liao G; Jiang Z; Yang Y; Zhang C; Jiang M; Zhu J; Xu L; Xie A; Yan M; Zhang Y; Xiao Y; Li X
BMC Med; 2021 Sep; 19(1):190. PubMed ID: 34465315
[TBL] [Abstract][Full Text] [Related]
10. Utility of Homologous Recombination Deficiency Biomarkers Across Cancer Types.
Takamatsu S; Brown JB; Yamaguchi K; Hamanishi J; Yamanoi K; Takaya H; Kaneyasu T; Mori S; Mandai M; Matsumura N
JCO Precis Oncol; 2021 Aug; 5():. PubMed ID: 34423229
[TBL] [Abstract][Full Text] [Related]
11. A Risk Model Developed Based on Homologous Recombination Deficiency Predicts Overall Survival in Patients With Lower Grade Glioma.
Peng H; Wang Y; Wang P; Huang C; Liu Z; Wu C
Front Genet; 2022; 13():919391. PubMed ID: 35846118
[TBL] [Abstract][Full Text] [Related]
12. Homologous Recombination Deficiency Associated With Response to Poly (ADP-ribose) Polymerase Inhibitors in Ovarian Cancer Patients: The First Real-World Evidence From China.
Ni J; Guo W; Zhao Q; Cheng X; Xu X; Zhou R; Gu H; Chen C; Chen X
Front Oncol; 2021; 11():746571. PubMed ID: 35070965
[TBL] [Abstract][Full Text] [Related]
13. Loss of heterozygosity as a marker of homologous repair deficiency in multiple myeloma: a role for PARP inhibition?
Pawlyn C; Loehr A; Ashby C; Tytarenko R; Deshpande S; Sun J; Fedorchak K; Mughal T; Davies FE; Walker BA; Morgan GJ
Leukemia; 2018 Jul; 32(7):1561-1566. PubMed ID: 29467487
[TBL] [Abstract][Full Text] [Related]
14. Optical Genome Mapping: Integrating Structural Variations for Precise Homologous Recombination Deficiency Score Calculation.
Sahajpal NS; Mondal AK; Vashisht A; Singh H; Pang AWC; Saul D; Nivin O; Hilton B; DuPont BR; Kota V; Savage NM; Hastie AR; Chaubey A; Kolhe R
Genes (Basel); 2023 Aug; 14(9):. PubMed ID: 37761823
[TBL] [Abstract][Full Text] [Related]
15. Homologous recombination deficiency and ovarian cancer.
Ledermann JA; Drew Y; Kristeleit RS
Eur J Cancer; 2016 Jun; 60():49-58. PubMed ID: 27065456
[TBL] [Abstract][Full Text] [Related]
16. Breast cancer brain metastases show increased levels of genomic aberration-based homologous recombination deficiency scores relative to their corresponding primary tumors.
Diossy M; Reiniger L; Sztupinszki Z; Krzystanek M; Timms KM; Neff C; Solimeno C; Pruss D; Eklund AC; Tóth E; Kiss O; Rusz O; Cserni G; Zombori T; Székely B; Kulka J; Tímár J; Csabai I; Szallasi Z
Ann Oncol; 2018 Sep; 29(9):1948-1954. PubMed ID: 29917049
[TBL] [Abstract][Full Text] [Related]
17. Biomarkers for Homologous Recombination Deficiency in Cancer.
Hoppe MM; Sundar R; Tan DSP; Jeyasekharan AD
J Natl Cancer Inst; 2018 Jul; 110(7):704-713. PubMed ID: 29788099
[TBL] [Abstract][Full Text] [Related]
18. Role of Poly (ADP-Ribose) Polymerase inhibitors beyond BReast CAncer Gene-mutated ovarian tumours: definition of homologous recombination deficiency?
Gourley C; Miller RE; Hollis RL; Ledermann JA
Curr Opin Oncol; 2020 Sep; 32(5):442-450. PubMed ID: 32796232
[TBL] [Abstract][Full Text] [Related]
19. Prediction of homologous recombination deficiency from cancer gene expression data.
Kang J; Lee J; Lee A; Lee YS
J Int Med Res; 2022 Nov; 50(11):3000605221133655. PubMed ID: 36380518
[TBL] [Abstract][Full Text] [Related]
20. Applicability of Anticancer Drugs for the Triple-Negative Breast Cancer Based on Homologous Recombination Repair Deficiency.
Liao G; Yang Y; Xie A; Jiang Z; Liao J; Yan M; Zhou Y; Zhu J; Hu J; Zhang Y; Xiao Y; Li X
Front Cell Dev Biol; 2022; 10():845950. PubMed ID: 35281113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
